Porphyria Educational Services
PORPHYRIA EDUCATIONAL SERVICES Bulletin Vol. 1 No. 13
March 1999
DENTAL ANESTHETICS AND THE PORPHYRIC
There are all kinds of anesthetics used by dentists for numbing
your gums while they work on your teeth. Some are very safe, but
a lot of the newer ones are considered unsafe. Why unsafe you ask?
Many of the newer drugs are combinations of the older ones put
together with others that are newer or are contraindicated for
porphyrics. Old-fashioned Novacaine is one thing, but having that
"caine" suffix included in newer dental anesthetics
does not make it safe.
It is most important to remember that COCAINE is definitely an
UNSAFE DRUG for porphyrics. Many of the drugs have trace amounts
of cocaine contained within their compound makeup.
The following are today's leading dental anesthetics. Since every
porphyric reacts to pharmaceuticals differently, These will be
left as they appear within the dental drug handbook.
RAVOCAINE® HCl 0.4% NOVOCAIN ® 2% with LEVOPHED® 1:30,000
PROPOXYCAINE HCl, PROCAINE HCl, and NOREPINEPHRINE BITARTRATE
INJECTION, USP This is manufactured by Cook-Waite from Kodak.
Description: A local anesthetic combination in the para-aminobenzoic
acid ester group, containing propoxycaine HCl 4 mg, procaine HCl
20 mg, norepinephrine bitartrate 0.067 mg.
Pharmacology: Stabilizes the neuronal membrane and prevents the
initiation and transmission of nerve impulses, thereby effecting
local anesthesia. The onset of action is usually 2-5 minutes, and
the duration of action is from 2-3 hours. Norepinephrine
bitartrate is a sympathomimetic amine suitable for use as a
vasoconstrictor in local anesthetic solutions. Indications: For
the production of local anesthesia for dental procedures by
infiltration injection or nerve block in adults and children.
Contraindications: Hypersensitivity to local anesthetics of the
para-aminobenzoic acid ester group.
Precautions: The lowest dose that results in effective anesthesia
should be used to avoid high plasma levels and serious
undesirable systemic side effects, hypertension, arteriosclerotic
heart disease, cerebral vascular insufficiency, heart block,
thyrotoxicosis, and diabetes. Contains a sulfite that may cause
allergic-type reactions including anaphylactic symptoms and life-threatening
or less severe asthmatic episodes in certain susceptible people.
Debilitated, elderly patients, acutely ill patients, and children
should be given reduced doses commensurate with their weight and
physical status.
Young children should be given minimal doses of both sedative and
anesthetics, if both are used. It should be remembered that young
children from porphyric families who have not yet been tested
should avoid any unsafe anesthetic.
Patients with a history of drug sensitivity or allergy, pregnancy
Category C, nursing mothers. Mild or even severe headaches may be
produced by the systemic action of norepinephrine.
Drug Interactions: MAO inhibitors, tricyclic antidepressants,
phenothiazines.
Adverse Reactions: CNS reactions are characterized by excitation
and/or depression. Nervousness, dizziness, blurred vision, or
tremors may occur followed by drowsiness, convulsions,
unconsciousness, and possibly respiratory arrest. Depression of
the myocardium, hypotension, profound bradycardia, and cardiac
arrest. Allergic reactions, characterized by cutaneous lesions of
delayed onset, or urticaria, edema, and other manifestations of
allergy.
MARCAINE® HCl 0.5% with EPINEPHRINE 1:200,000 (BUPIVACAINE and
EPINEPHRINE INJECTION, USP)
Cook-Waite from Kodak Description: Marcaine is related chemically
and pharmacologically to the aminoacyl local anesthetics. It is a
homologue of mepivacaine and is chemically related to lidocaine.
All three of these anesthetics contain an amide linkage between
the aromatic nucleus and the amino or piperdine group.
Pharmacology: Marcaine stabilizes the neuronal membrane and
prevents the initiation and transmission of nerve impulses,
thereby effecting local anesthesia. The onset of action following
dental injections is usually 2-10 minutes and anesthesia may last
2 or 3 times longer than lidocaine and mepivacaine for dental use,
in many patients up to 7 hours. The duration of anesthetic effect
is prolonged by the addition of epinephrine 1:200,000.
Indications: For the production of local anesthesia for dental
procedures binfiltration injection or nerve block in adults.
Contraindications: Hypersensitivity to it or to any local
anesthetic agent of the amide-type or to other components of
MARCAINE solutions.
Precautions: Existence of hypertension, arteriosclerotic heart
disease, cerebral vascular insufficiency, heart block,
thyrotoxicosis and diabetes, patients receiving drugs likely to
produce alterations in blood pressure. Not recommended for
children under 12. Contains a SULFITE that may cause allergic-type
reactions. **Remember that porphyrics can not use any of the
Sulpha containing type drugs. Debilitated, elderly patients and
acutely ill patients should be given reduced doses. Patients
should be cautioned about the possibility of inadvertent trauma
to tongue, lips, and buccal mucosa and advised not to chew solid
foods or test the anesthetized area by biting or probing. Changes
in sensorium such as excitation, disorientation, drowsiness may
be early indications of a high blood level of the drug and may
occur following inadvertent intravascular administration or rapid
absorption. Use cautiously in areas with limited blood supply.
Peripheral vascular disease, severe LIVER disease.
**Please note that hepatic porphyrias are considered liver
disease.
Use with caution when there is inflammation and/or sepsis in the
region of the proposed injection.
.
Drug Interactions: Monoamine oxidase inhibitors, tricyclic
antidepressants, vasopressor drugs, ergot-type oxytocic drugs,
phenothiazines, butyrophenones.
Adverse Reactions: Blood pressure changes (usually hypotension),
cardiac arrest, allergic reactions, hypersensitivity, transient
facial swelling and puffiness, CNS reactions are characterized by
excitation or depression. Nervousness, dizziness, blurred vision,
or tremors, followed by drowsiness, convulsions, unconsciousness,
and possibly respiratory arrest. Nausea, vomiting, chills,
constriction of the pupils, tinnitus, depression of the
myocardium, edema.
LIDOCAINE HCl 2% and EPINEPHRINE 1:50,000 INJECTION LIDOCAINE HCl
2% and EPINEPHRINE 1:100,000 INJECTION (LIDOCAINE and EPINEPHRINE
INJECTION,USP)
Cook-Waite from Kodak Description: Lidocaine HCl injections are
sterile nonpyrogenic isotonic solutions that contain a local
anesthetic agent with epinephrine (as bitartrate) and are
administered parenterally by injection.
Pharmacology: Lidocaine stabilizes the neuronal membrane by
inhibiting the ionic fluxes required for the initiation and
conduction of impulses, thereby effecting local anesthetic action.
Onset and duration of anesthesia: infiltration anesthesia, time
of onset averages less than 2 minutes. Lidocaine provides an
average pulp anesthesia of at least 60 minutes with an average
duration of soft tissue anesthesia of approximately 2.5 hours.
When used for nerve block the time of onset averages 2-4 minutes
Lidocaine provides an average pulp anesthesia of at least 90
minutes with an average duration of soft tissue anesthesia of 3.25
hours.
Contraindications: Hypersensitivity to local anesthetics of the
amide type.
Precautions: Contains sodium metabisulfite, a SULFITE that may
cause allergic-type reactions. [*Remember again that this is a
part of the Sulfa family of drugs.] Debilitated, elderly patients,
acutely ill patients, and children should be given reduced doses
commensurate with their age and physical condition. Used with
caution in patients with severe shock or heart block. Used
cautiously in areas of the body supplied by end arteries or
having otherwise compromised blood supply, or patients with
peripheral vascular disease, hypertensive vascular disease,
hepatic disease, or impaired cardiovascular function.
Drug Interactions: Monoamine oxidase inhibitors, tricyclic
antidepressants or phenothiazines, vasopressor drugs, ergot-type
oxytocic drugs.
Adverse Reactions: CNS manifestations are excitatory and/or
depressant characterized by lightheadedness, nervousness,
apprehension, euphoria, confusion, dizziness, drowsiness,
tinnitus, blurred or double vision, vomiting, sensations of heat,
cold or numbness, twitching, tremors, convulsions,
unconsciousness, respiratory depression and arrest. Drowsiness is
usually an early sign of high blood level. Bradycardia,
hypotension, and cardiovascular collapse which may lead to
cardiac arrest. Allergic reactions are characterized by cutaneous
lesions, urticaria, edema or anaphylactoid reactions and are
extremely rare.
DURANEST® (ETIDOCAINE HCl) INJECTIONS FOR INFILTRATION AND NERVE
BLOCK By Astra Description: Sterile aqueous solutions that
contain a local anesthetic agent and are administered
parenterally by injection.
Pharmacology: Etidocaine stabilized the neuronal membrane by
inhibiting the ionic fluxes required for the initiation and
conduction of impulses, thereby effecting local anesthetic action.
Has a rapid onset (3-5 minutes) and prolonged duration of action
(5-10 hours). Initial onset of sensory analgesia and motor
blockade is rapid (usually 3-5 minutes) and similar to that
produced by lidocaine.
Indications: Solutions are indicated for infiltration anesthesia,
peripheral nerve blocks, and central neural block.
Contraindications: Hypersensitivity to local anesthetics of the
amide type.
Precautions: To avoid intravascular injection, aspiration should
be performed before the local anesthetic solution is injected.
Contains sodium metabisufite, a SULFITE that may cause allergic-type
reactions.[**Again remember this is from the Sulfa family of
drugs.] The lowest dosage that results in effective anesthesia
should be used.
Debilitated, elderly patients, acutely ill patients, and children
should be given reduced doses commensurate with their age and
physical condition. Use with caution in patients with severe
shock or heart block, existing neurological disease, spinal
deformities, septicemia, severe hypertension, peripheral vascular
disease. Areas of the body supplied by end arteries or having
otherwise compromised blood supply. Severe hepatic disease,
impaired cardiovascular function. May be a potential triggering
agent for familial malignant hyperthemia.
Drug Interactions: Monoamine oxidase inhibitors, tricyclic
antidepressants or phenothiazines, vasopressor drugs, ergot-type
oxytocic drugs.
Adverse Reactions: CNS manifestations are excitatory and/or
depressant and may be characterized by lightheadedness,
nervousness, apprehension, euphoria, confusion, dizziness,
drowsiness, tinnitus, blurred or double vision, vomiting.
Cardiovascular manifestations are usually depressant and are
characterized by bradycardia, hypotension, and cardiovascular
collapse which may lead to cardiac arrest. Allergic reactions are
usually characterized by cutaneous lesions, uticaria, edema or
anaphylactoid reactions. Drowsiness following the administration
of etidocaine is usually an early sign of high blood level of the
drug and may occur as a consequence of rapid absorption.
DYCLONE (DYCLONINE HCl) 0.5% and 1% TOPICAL SOLUTIONS, USP Astra
Description: A local anesthetic agent administered topically.
Dyclone 0.5% solution contains dyclonine HCl, 5 mg. Dyclone 1%
solution contains dyclonine HCl, 10 mg.
Pharmacology: Affect surface anesthesia when applied topically to
mucous membranes. Anesthesia usually occurs from 2-10 minutes
after application and persists for approximately 30 minutes.
Indications: For anesthetizing accessible mucous membranes. May
also be used to block the gag reflex, to relieve the pain of oral
ulcers or stomatitis, and to relieve pain associated with
anogenital lesions. Useful as a preinjection mucous membrane
anesthetic or applied to the gums prior to scaling (prophylaxis).
Contraindications: Hypersensitivity to the local anesthetic or to
other components of Dyclone solutions.
Precautions: Should not be injected into tissue or used in the
eyes because of highly irritant properties.Use with extreme
caution in the presence of sepsis or severely traumatized mucosa
in the area of application since under such conditions there is
the potential for rapid systemic absorption. Patients with severe
shock or heart block. mothers. Safety and effectiveness in
children under 12 have not been established.
Adverse Reactions: CNS manifestations are excitatory and/or
depressant and may be characterized by lightheadedness,
nervousness, apprehension, euphoria, confusion, dizziness,
drowsiness, tinnitus, blurred or double vision, vomiting,
sensations of heat, cold, or numbness. Drowsiness following the
administration of Dyclone is usually an early sign of a high
blood level of the drug and may occur as a consequence of rapid
absorption. Cardiovascular manifestations are usually depressant
and are characterized by bradycardia, hypotension.
CITANEST® FORTE (PRILOCAINE and EPINEPHRINE INJECTION, USP) 4%
INJECTION with EPINEPHRINE 1:200,000 Astra CITANEST® PLAIN(PRILOCAINE
HCP) INJECTION, USP) 4% INJECTION Astra Description: Citanest
Plain is a sterile isotonic solution containing 4% prilocaine HCl.
Citanest Forte contains 4% prilocaine HCl and a vasoconstrictor,
epinephrine (as bitartrate). Citanest Plain-maximum pain control
averaging 20 minutes (infiltration), 60 minutes (nerve block).
Pharmacology: Prilocaine stabilizes the neuronal membrane by
inhibiting the ionic fluxes required for the initiation and
conduction of nerve impulses, thereby effecting local anesthetic
action. Onset and duration of action: When used for infiltration
injection in dental patients, the time of onset of anesthesia
with Citanest Contraindications: Hypersensitivity to local
anesthetics of the amide type or to any components of the
injectable formulations, and in those rare patients with
congenital or idiopathic methemoglobinemia.
Precautions: Citanest Forte contains a SULFITE that may cause
allergic-type reactions including anaphylactic symptoms.
Debilitated, elderly patients, acutely ill patients, and children
should be given reduced doses commensurate with their age and
physical condition. Patients with severe shock or heart block,
vasoconstrictor should be used with caution in areas of the body
supplied by end arteries or having otherwise compromised blood
supply, peripheral vascular disease, hypertensive vascular
disease, potent general anesthetic agents. Restlessness, anxiety,
tinnitus, dizziness, blurred vision, tremors, depression or
drowsiness should alert the practitioner to the possibility of
central>nervous system toxicity. Hepatic disease, pregnancy
Category B, nursing mothers. Drowsiness following the
administration of prilocaine is usually an early sign of a high
blood level of the drug and may occur as a consequence of rapid
absorption. Cardiovascular manifestations are usually depressant
and are characterized by bradycardia hypotension and
cardiovascular collapse, which may lead to cardiac arrest.
Drug Interactions: MAO inhibitors, tricyclic antidepressants,
phenothiazines, vasopressor drugs, ergot-type oxytocic drugs.
Adverse Reactions: Allergic reactions are characterized by
cutaneous lesions, urticaria, edema or anaphylactoid reactions.
CNS manifestations are excitatory and/or depressant and may be
characterized by lightheadedness, nervousness, apprehension,
euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or
double vision, vomiting, sensations of heat, cold or numbness,
twitching, tremors, convulsions, unconsciousness, respiratory
depression and arrest. Swelling and persistent parasthesia of the
lips and oral tissue may occur.
CITANEST® FORTE (PRILOCAINE and EPINEPHRINE INJECTION, USP) 4%
INJECTION with EPINEPHRINE 1:200,000 Astra CITANEST® PLAIN (PRILOCAINE
HCL INJECTION, USP) 4% INJECTION Astra Description: Citanest
Plain is a sterile isotonic solution containing 4% prilocaine HCl.
Citanest Forte contains 4% prilocaine HCl and a vasoconstrictor,
epinephrine (as bitartrate). Citanest Plain-maximum pain control
averaging 20 minutes (infiltration), 60 minutes (nerve block).
Pharmacology: Prilocaine stabilizes the neuronal membrane by
inhibiting the ionic fluxes required for the initiation and
conduction of nerve impulses, thereby effecting local anesthetic
action. Citanest Forte injections averages less than 3 minutes,
with an average Contraindications: Hypersensitivity to local
anesthetics of the amide type or to any components of
theinjectable formulations, and in those rare patients with
congenital or idiopathic methemoglobinemia.
Precautions: Citanest Forte contains a sulfite that may cause
allergic-type reactions including anaphylactic symptoms.
Debilitated, elderly patients, acutely ill patients, and children
should be given reduced doses commensurate with their age and
physical condition. Patients with severe shock or heart block,
vasoconstrictor should be used with caution in areas of the body
supplied by end arteries or having otherwise compromised blood
supply, peripheral vascular disease, hypertensive vascular
disease, potent general anesthetic agents. Restlessness, anxiety,
tinnitus, dizziness, blurred vision, tremors, depression or
drowsiness should alert the practitioner to the possibility of
central nervous system toxicity. Hepatic disease, pregnancy
Category B, nursing mothers. Drowsiness following the
administration of prilocaine is usually an early sign of a high
blood level of the drug and may occur as a consequence of rapid
absorption. Cardiovascular manifestations are usually depressant
and are characterized by bradycardia hypotension and
cardiovascular collapse, which may lead to cardiac arrest.
Drug Interactions: MAO inhibitors, tricyclic antidepressants,
phenothiazines, vasopressor drugs, ergot-type oxytocic drugs.
Adverse Reactions: Allergic reactions are characterized by
cutaneous lesions, urticaria, edema or anaphylactoid reactions.
CNS manifestations are excitatory and/or depressant and may be
characterized by lightheadedness, nervousness, apprehension,
euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or
double vision, vomiting, sensations of heat, cold or numbness,
twitching, tremors, convulsions, unconsciousness, respiratory
depression and arrest. Swelling and persistent parasthesia of the
lips and oral tissue may occur.
CARBOCAINE® HCl 3% INJECTION (MEPIVACAINE HCl INJECTION, USP)
Cook-Waite from Kodak CARBOCAINE® HCl 2% WITH NEO-COBEFRIN® 1:20,000
INJECTION (MEPIVACAINE HCl and LEVONORDEFRIN INJECTION, USP) Cook-Waite
from Kodak.
Description: Mepivacaine HCl is a tertiary amine used as a local
anesthetic. Levonordeferin is a sympathomimetic amine used as a
vasoconstrictor in local anesthetic solutions. Carbocaine® 3% 30
mg per ml mepivacaine HCl. Carbocaine® 2% with Neo-Cobefrin® 20
mg per ml mepivacaine HCl, 0.05 mg per ml levonordefrin.
Pharmacology: Carbocaine stabilizes the neuronal membrane and
prevents the initiation and transmission of nerve impulses,
thereby effecting local anesthesia.
.
Indications: Production of local anesthesia for dental procedures
by infiltration or nerve block in adults and children.
Contraindications: Hypersensitivity to amide-type local
anesthetics.
Precautions: Contains a vasoconstrictor that should be used with
extreme caution, existence of hypertension, arteriosclerotic
heart disease, cerebral vascular insufficiency, thyrotoxicosis
and diabetes. Contains a SULFITE that may cause allergic-type
reactions. The lowest dose that results in effective anesthesia
should be used. Debilitated, elderly patients, acutely ill
patients, and children should be given reduced doses commensurate
with their weight and physical status. History of severe
disturbances of cardiac rhythm or heart block. Reduce doses if
sedatives are employed. Changes in sensorium such as excitation,
disorientation, drowsiness, may be early indications of a high
blood level of the drug and may occur following inadvertent
intravascular administration or rapid absorption of mepivacaine.
Inflammation and/o.sepsis in the region of the proposed
injections, Drug Interactions: Tricyclic antidepressants,
monoamine oxidase inhibitors, ergot-type oxytocic drugs,
phenothiazines, butyrophenones.
Adverse Reactions: CNS reactions are characterized by excitation
and/or depression. Nervousness, dizziness, blurred vision, or
tremors may occur followed by drowsiness, convulsions,
unconsciousness, and possibly respiratory arrest, cardiovascular
reactions are depressant. Anaphylactoid reactions to CARBOCAINE
have occurred rarely.
All porphyrics must read these dental informational
scjedules and then double-check against the latest UNSAFE DRUG
lists.
Again, most of the dental anesthetics copntain sulfites and are a
part of the SULFA DRUG family which have been traditionally
unsafe for porphyrics.